BCL2 and B-cell chronic lymphocytic leukemia: High expression of endogenous BCL2 may inhibit ribonucleotide reductase activity, thereby reducing the pool of intracellular dNTPs.38 CLL cells are known to express high levels of BCL2 protein, and hence may be particularly sensitive to DNA damage.